PWM
FDMT icon

Perigon Wealth Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Perigon Wealth Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94M Sell
146,185
-12
-0% -$117 0.03% 419
2026
Q1 		$1.36M Buy
146,197
+64
+0% +$557 0.02% 451
2025
Q4 		$1.1M Hold
146,133
– – 0.02% 512
2025
Q3 		$1.27M Hold
146,133
– – 0.03% 448
2025
Q2 		$542K Hold
146,133
– – 0.01% 646
2025
Q1 		$472K Hold
146,133
– – 0.01% 655
2024
Q4 		$684K Sell
146,133
-37
-0% -$290 0.02% 550
2024
Q3 		$1.58M Hold
146,170
– – 0.04% 326
2024
Q2 		$3.07M Buy
146,170
+20
+0% +$502 0.09% 199
2024
Q1 		$4.66M Sell
146,150
-100,000
-41% -$2.55M 0.14% 151
2023
Q4 		$4.99M Hold
246,150
– – 0.16% 130
2023
Q3 		$3.13M Buy
246,150
+75
+0% +$1.25K 0.13% 157
2023
Q2 		$4.45M Hold
246,075
– – 0.17% 126
2023
Q1 		$4.23M Hold
246,075
– – 0.24% 94
2022
Q4 		$5.47M Sell
246,075
-4,400
-2% -$68K 0.34% 72
2022
Q3 		$2.01M Sell
250,475
-98,271
-28% -$890K 0.17% 121
2022
Q2 		$2.43M Sell
348,746
-208,729
-37% -$2.03M 0.2% 104
2022
Q1 		$8.43M Sell
557,475
-209,492
-27% -$3.29M 0.6% 30
2021
Q4 		$16.8M Buy
+766,967
New +$18.8M 1.2% 13

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Perigon Wealth Management's FDMT Position: Q2 2026 in Review

Perigon Wealth Management reduced its 4D Molecular Therapeutics (FDMT) stake by 0.01% in Q2 2026, selling an estimated $117 and leaving 146,185 shares worth $1.94M. The position accounts for 0.03% of the portfolio, ranked #419.

Perigon Wealth Management first reported a position in FDMT in Q4 2021 and has held it in 19 quarters since. The position peaked at $16.8M in Q4 2021. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Perigon Wealth Management held 146,185 shares of 4D Molecular Therapeutics worth $1.94M as of Q2 2026.
  • Perigon Wealth Management sold 12 4D Molecular Therapeutics shares in Q2 2026, an estimated $117.
  • 4D Molecular Therapeutics made up 0.03% of Perigon Wealth Management's portfolio in Q2 2026, its #419 holding.
  • Perigon Wealth Management first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Perigon Wealth Management's 4D Molecular Therapeutics position peaked at $16.8M in Q4 2021.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.